Razlika u učestalosti recidiviranja mišićno-neinvazivnih tumora mokraćne bešike zavisno od optimalne primene intravezikalne imunoterapije bacilom Calmette-Guérin

  • Radovan Milošević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Novak Milović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Predrag Aleksić Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Miodrag Lazić Department of Urology, Hospital Dr Dragiša Mišović, Belgrade, Serbia
  • Snežana Cerović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Institute for Pathology, Military Medical Academy, Belgrade, Serbia
  • Vladimir Bančević Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia; Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Branko Košević Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Predrag Marić Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Aleksandar Spasić Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Dejan Simić Clinic of Urology, Military Medical Academy, Belgrade, Serbia
  • Božidar Kovačević Institute for Pathology, Military Medical Academy, Belgrade, Serbia
DOI: https://doi.org/10.2298/4776
Ključne reči: urinary bladder, neoplasms||, ||mokraćna bešika, neoplazme, carcinoma in situ||, ||karcinom in situ, immunotherapy||, ||imunoterapija, mycobacterium bovis||, ||bacillus calmetteguerin, recurrence||, ||recidiv,

Sažetak


Uvod/Cilj. Intravezikalna imunoterapija bacilom Calmette-Guérin (BCG) smatra se zlatnim standardom u lečenju mišićnoneinvazivnih tumora mokraćne bešike (NIMBC) nakon transuretralne resekcije (TUR) tumora. Cilj istraživanja bio je uporediti učestalost recidiviranja tumora između bolesnika podvrgnutih terapiji TUR + BCG (grupa I) i samo terapiji TUR (grupa II). Metode. Bolesnici sa NIMBC lečeni u našoj instituciji od 1. 1. 2007. do 3. 3. 2013. (n = 899), bili su uključeni u istraživanje. Dve grupe bolesnika podeljene su u tri podgrupe: bolesnike sa solitarnim novootkrivenim tumorima ≤ 3 cm (SFDGT), bolesnike sa solitarnim novootkrivenim tumorima > 3 cm i multiplim novootkrivenim tumorima (MFDGT), i bolesnike sa recidivnim tumorima (RCT). Statistička analiza obavljena je primenom χ2-testa i Kolmogorov-Smirnov testa. Rezultati. U grupi I došlo je do recidiva kod 133 bolesnika, nasuprot 75 u grupi II, što je statistički visokoznačajna razlika. Ako se analizira učestalost recidiviranja uzimajući u obzir formirane podgrupe nađeno je da se u grupi I SFDGT recidiv javio kod 27 bolesnika, nasuprot 9 bolesnika u grupi II (p > 0,05) u grupi I MFDGT recidiv se desio kod 49 bolesnika nasuprot 31 u grupi II (p < 0,001) kao i da se u grupi I RCT recidiv javio kod 57 bolesnika nasuprot 35 u grupi II (p < 0,001). Zaključak. Dobijeni rezultati ukazuju da ne postoji statistički značajna razlika u učestalosti recidiviranja kod podgrupe SFDGT, ali je prisutna kod podgrupa MFDGT i RCT. Ovo može biti od značaja za svakodnevnu kliničku praksu.

Reference

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes J, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3): 466−75.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54(2): 303−14.

Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61(6): 299−305.

Vázquez-Lavista LG, Flores-Balcázar CH, Llorente L. The bacillus Calmette-Guérin as immunomodulator in bladder cancer. Rev Invest Clin 2007; 59(2): 146−52.

Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol 2007; 34(2): 165−72.

Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169(1): 90−5.

Ströck V, Dotevall L, Sandberg T, Gustafsson CK, Holmäng S. Late bacille Calmette-Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treat-ment. BJU Int 2011; 107(10): 1592−7.

Herr HW, Morales A. Hystory of bacillus Calmette-Guérin and bladder cancer: an immunotherapy succes story. J Urol 2008; 179(1): 53−6.

Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57(3): 410−29.

Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147(3): 596−600.

Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2): 180−3.

Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124(1): 38−40.

Ríos GE, Martínez-Piñeiro LL, Martínez-Piñeiro CJ, de la Peña BJ. Immunotherapy in superficial bladder carcinoma. Arch Esp Urol 2000; 53(10): 879−92.

Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come. CA Cancer J Clin 2010; 60(4): 244−72.

Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010; 36(3): 195−205.

Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67(6): 1216−23.

Lamm DL, Colombel M, Persad R, Solowayd M, Böhlee A, Palouf J. Clinical practise recommendations for the menagment of non-muscle invasive bladder cancer. Eur Urol Suppl 2008; 7(10): 651−66.

Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk su-perficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52(5): 1398−406.

Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174(4 Pt 1): 1242−7.

Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41(5): 523−31.

Objavljeno
2015/07/08
Broj časopisa
Vol. 72 Br. 3 (2015)
Rubrika
Originalni članak